EducationHigh Doses of Taurolidine Inhibit Advanced Intraperitoneal Tumor Growth in Rats
Introduction
Different anti-tumorigenic substances have been examined and analyzed over the last few years in animal experiments. The side effects of the chemotherapeutic agents used can be a major problem in antineoplastic therapy. Taurolidine (TRD), a synthetic product derived from the aminosulfone acid taurine, consists of two aromatic rings, which are connected with a CH2-group [1]. The substance was found to suppress the growth of various abdominal tumor cell lines [2], malignant glioma [3], and human squamous cell carcinoma in vitro and in vivo [4].
It has been shown that the tumor necrosis factor α (TNFα) production and the vascular endothelial growth factor level (VEGF) could also be reduced in colonic tumor cells (DHD/K12/TRb) [5]. Although the underlying antitumor mechanisms have not been explained exactly, TRD significantly inhibited intraperitoneal tumor growth in early stages of the disease in rats [6, 7, 8, 9], reduced pancreatic cancer progression in hamsters [10, 11], and effectively inhibited subcutaneous xenograft tumor growth in mice [12]. Other studies confirmed that cytotoxic effects were not observed in physiological cells after single administration such as human fibroblasts [2].
Local therapy of TRD has been shown to reduce intraperitoneal tumor growth without side effects in animals [2, 6]. Other animal studies performed by our working group investigated the effects of a single intravenous injection of TRD (0.5%) on tumor growth in laparoscopy or laparotomy [8, 9]. It seems that only a direct contact of the substance with the tumor cells can inhibit tumor growth when low doses are used. Although TRD was found to induce apoptosis [6], the used intravenous low-dose TRD injections did not inhibit neither intraperitoneal nor subcutaneous tumor growth. In the current study our aim was to investigate the role of TRD on established tumor loads.
Reflecting these remarkable anti-tumorigenic and specific effects, we hypothesized that TRD could be used as an interesting long-term therapy agent in advanced tumor stages or even metastases. In a first study (experiment A) the antitumor potential of increasing intravenously and intraperitoneally administered doses were evaluated. The possible toxic effects on the liver, the kidneys, and the superior vena cava (SVC) were histologically examined, scored, and presented. A second study (experiment B) analyzed the effects on intraperitoneal tumor growth in progressive tumor stages after a long-term intravenous and intraperitoneal therapy in rats. To investigate side effects, body weight changes and peripheral blood were taken to analyze the differential blood counts.
Section snippets
Experiment A
This study was investigated to evaluate the organ toxicity of increasing taurolidine doses. The therapy agents were prepared as recommended by the manufacturer as described in experiment B.
Experiment A
No animal died during this toxicity study.
Experiment B
No animal died during the different long-term therapy strategies.
Discussion
Taurolidine was found to exert antibiotic and anti-tumorigenic effects on different prokaryotic and eukaryotic cells [1]. It suppresses tumor growth in many cell lines [2, 4, 10, 12, 15] and reduces the TNFα production in mesangial rat cell cultures [16] and by malignant colonic tumor cells with an IC50 value of 0.5 mm. Additionally, the major pro-angiogenetic factor VEGF production was also reduced within a 6-h contact (IC50 1.5 mm) [5]. Many data showed a selective influence on various tumor
Acknowledgments
We thank Professor Dr. J. M. Mueller, the Director of the Department of Surgery, and Professor Dr. W. Dubiel, the Chief of the Division of Molecular Biology, for continuous support.[18, 19]
References (33)
- et al.
Effects of taurolidine and octreotide on tumor growth and lipid peroxidation after staging-laparoscopy in ductal pancreatic cancer
Prostaglandins Leukot. Essent. Fatty Acids
(2003) - et al.
The Banff 97 working classification of renal allograft pathology
Kidney Int
(1999) - et al.
Taurolidine improves survival by abrogating the accelerated development and proliferation of solid tumor and development of organ metastases from circulating tumor cells released following surgery
J. Surg. Res
(2001) - et al.
Taurolidine. An analogue of the amino acid taurine, suppresses interleucin-1 and tumor necrosis factor synthesis in human peripheral blood mononuclear cells
Cytokine
(1991) - et al.
Human peritoneal mesothelial cells produce many cytokines (granulocyte colony-stimulating factor, granulocyte-monocyte CSF, macrophage CSF, IL-1 and IL-2) and are activated and stimulated to grow by IL-1
Blood
(1992) - et al.
Inhibition of TNF-induced apoptosis by NF-kappa B
Trends Cell Biol
(1998) Einführung und Übersicht
- et al.
Taurolidinecytotoxic and mechanistic evaluation of a novel antineoplastic agent
Cancer Res
(2001) - et al.
The effect of taurolidine on brain tumor cells
Anticancer Res
(2002) - et al.
In-vitro-effect von Taurolidin auf Plattenepithelkarzinomzellen der Mundhöhle
Mund Kiefer GesichtsChir
(2003)
The tumour suppressive reagent taurolidine is an inhibitor of protein biosynthesis
Int. J. Cancer
New therapeutic strategies to avoid intra- and extraperitoneal metastases during laparoscopyresults of a tumor model in the rat
Dig. Surg
Influence of different gases and intraperitoneal instillation of antiadherent or cytotoxic agents on peritoneal tumor cell growth and implantation with laparoscopic surgery in a rat model
Surg. Endosc
Local and systemic chemotherapy with taurolidine and taurolidine/heparin in colon cancer-bearing rats undergoing laparotomy
Clin. Exp. Metastasis
Influence of intraperitoneal and systemic application of taurolidine and taurolidine/heparin during laparoscopy on intraperitoneal and subcutaneous tumour growth in rats
Clin. Exp. Metastasis
Effects of taurolidine and octreotide on port site and liver metastasis after laparoscopy in an animal model of pancreatic cancer
Clin. Exp. Metastasis
Cited by (20)
An Evaluation of Normal Saline and Taurolidine on Intra-Abdominal Adhesion Formation and Peritoneal Fibrinolysis
2008, Journal of Surgical ResearchCitation Excerpt :Taurolidine is derived from taurine, a natural amino acid. This agent was found to suppress the growth of various abdominal tumor cell lines [8], malignant glioma [9], and human squamous cell carcinoma in vitro and in vivo [10, 11]. Peritoneal administration of normal saline mostly served as control in previous investigations.
The Tumor Suppressive Reagent Taurolidine Inhibits Growth of Malignant Melanoma-a Mouse Model
2007, Journal of Surgical ResearchCitation Excerpt :It is worth mentioning that the TRD 2% led to the most prominent reduction of sc tumor growth after i.p. administration. Although the therapy with 3% TRD solution seems to have a clear antineoplastic effect on intraperitoneal tumor growth [32], the 2% TRD solution should be preferred for administration because it is associated with less local toxicity. The 2% solution is stable and safe under room temperature for months, whereas 3% TRD has to be prepared in an extensive process just before use and can precipitate.
Does taurolidine have any effect on liver regeneration and oxidation in the experimental hepatectomy model?
2021, Turkish Journal of SurgeryEffect of N-(D-Ribopyranosyl)taurine sodium salt supplementation on the hepatic antioxidant system in rat models of diet-induced obesity and taurine deficiency
2015, Advances in Experimental Medicine and BiologyTaurolidine cooperates with antineoplastic drugs in neuroblastoma cells
2014, Genes and Cancer